- Current report filing (8-K)
December 15 2009 - 4:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 9, 2009
CYCLACEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-50626
|
|
91-1707622
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
200 Connell Drive, Suite 1500
Berkeley Heights, New Jersey
|
|
07922
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(908) 517-7330
|
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 3.01
|
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer or Listing.
|
On December 9, 2009, Cyclacel Pharmaceuticals, Inc. (the
Company
) received a determination letter from
the NASDAQ Listing Qualifications Staff (the
Staff
) at The NASDAQ Stock Market LLC (
NASDAQ
)
notifying the Company that it does not comply with the $10 million minimum stockholders equity requirement of the
continued listing rules of The NASDAQ Global Market (
Listing Rules
) set forth in NASDAQ Marketplace Rule
5450(b)(1)(A), and that the Companys securities are subject to delisting, unless the Company appeals the Staffs
determination to the NASDAQ Listing Qualifications Panel (the
Panel
) by no later than December 16, 2009.
The Company intends to request a hearing before the Panel by no later than December 16, 2009, consistent with
instructions contained in the determination letter, which will stay the Staffs determination to delist the Companys
securities on The NASDAQ Global Market pending the issuance of the Panels decision. Under NASDAQs Listing Rules, the
Panel may, at its discretion, determine to continue the listing of the Companys securities on The NASDAQ Global Market
for a maximum of 180 days from the date of the NASDAQs determination letter, or through June 7, 2010. There can,
however, be no assurance that the Panel will grant the Companys request for continued listing.
On December 15, 2009, the Company issued a press release announcing its receipt of NASDAQs determination letter.
A copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01
|
|
Financial Statements and Exhibits.
|
(d) Exhibits:
The following exhibit is furnished herewith:
99.1 Press release, dated December 15, 2009
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
CYCLACEL PHARMACEUTICALS, INC.
By:
/s/ Paul McBarron
Name: Paul McBarron
Title: Executive Vice President Finance,
Chief Financial Officer and Chief
Operating Officer
Date: December 15, 2009
3
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Apr 2024 to May 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From May 2023 to May 2024